The Company is focussed on creating novel medicines addressing complex intra-cellular targets in a wide range of diseases. Its proprietary platform technology is based on a combination of chemistry and synthetic biology deploying a set of rationally engineered enzymes.
GyreOx's experienced and successful management team will bring new therapeutics to market to address this opportunity using its proprietary discovery platform to create its unique GyrocycleTM molecules.
GyreOx Ltd. was founded in May 2019 to commercialise the technological breakthroughs made by its scientific founders, Professor James Naismith, University of Oxford, and Professor Marcel Jaspars, University of Aberdeen.
We have secured our first seed investment, and have been awarded a Technology Development Accelerator Award by Innovate UK.
This support will enable us to:
- automate our platform to allow creation of focussed libraries of GyrocycleTM macrocyclic peptides (100's per library);
- commercially validate the technology through revenue-generating discovery alliances with already engaged Pharma;
- optimise a lead in our first in-house cancer program;
- acquire and develop further drug targets.
